Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults - Full Text View

Purpose

Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety and immune response to the dengue vaccine DEN4delta30-4995 in healthy adults.

Condition	Intervention	Phase
Dengue	Biological: rDEN4delta30-4995 Biological: Placebo	Phase I

MedlinePlus related topics:

Dengue Fever Hemorrhagic Fevers

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-4995, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:

Frequency of vaccine-related adverse events, graded by severity for each dose [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
Immunogenicity of the rDEN4delta30-4995 vaccine against DEN4 virus by measurement of plaque reduction neutralization titers (PRNT) [ Time Frame: At Days 28 and 42 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Durability of antibody responses to DEN4 virus [ Time Frame: At Month 6 ] [ Designated as safety issue: No ]
Frequency, quantity, and duration of viremia in each dose cohort studied based on the mean peak viremia, mean day onset of viremia, and mean duration of viremia of each dose cohort [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
Number of vaccinees infected with the rDEN4delta30-4995 chimeric vaccine [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Estimated Enrollment:	84
Study Start Date:	January 2007
Estimated Primary Completion Date:	January 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^5 PFU dose) into the deltoid region of either arm.	Biological: rDEN4delta30-4995 Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
2: Experimental One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.	Biological: rDEN4delta30-4995 Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
3: Experimental One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.	Biological: rDEN4delta30-4995 Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
4: Placebo Comparator One subcutaneous vaccination with placebo into the deltoid region of either arm.	Biological: Placebo Placebo for rDEN4delta30-4995

Detailed Description:

Dengue viruses account for more than 50 million cases of dengue fever and a half million cases of the more severe disease, dengue hemorrhagic fever/dengue shock syndrome. Infection with dengue viruses is the leading cause of hospitalization and death in children in at least eight Asian countries. The goal of producing a vaccine against dengue fever is to induce a long-lived antibody response against all four dengue serotypes. The rDEN4delta30-4995 vaccine candidate is a live attenuated recombinant virus derived from rDEN4delta30 for protection against dengue virus serotype 4. The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of rDEN4delta30-4995 in healthy adults.

This study will last 180 days (6 months). Participants in Cohort 1 will be randomly assigned to receive the highest dose of rDEN4delta30 or placebo at study entry. Participants in Cohort 2 will be randomly assigned to receive a lower dose of rDEN4delta30 or placebo. Participants in Cohort 3 will be randomly assigned to receive the lowest dose of rDEN4delta30 or placebo. Cohorts 2 and 3 will begin after a safety review of all participants in the previous cohort.

After initial vaccination, participants in Cohort 1 will be followed every other day for the first 16 days of the study, monitoring their temperature three times a day through Day 16 and recording these measurements in a diary. After Day 16, study visits will occur on Days 21, 28, 42, and 180 and will include a physical exam and blood collection. Some participants will also be asked to undergo a skin biopsy or additional blood collection at selected visits.

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Adult males and non-pregnant females between 18 and 50 years of age
Good general health
Available for the duration of the study
Willing to use acceptable methods of contraception for the duration of the study

Exclusion Criteria:

Significant neurologic, cardiac, lung, liver, rheumatologic, autoimmune, or kidney disease
Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, may interfere with the study
Significant laboratory abnormalities
Medical, work, or family problems as a result of alcohol or illegal drug use within 12 months prior to study entry
History of severe allergic reaction or anaphylaxis
Severe asthma
HIV-1 serotype infected
Hepatitis C virus (HCV) infected
Hepatitis B surface antigen positive
Immunodeficiency syndrome
Use of corticosteroids or immunosuppressive medications within 2 weeks prior to study entry. Individuals using topical or nasal corticosteroids are not excluded.
Live vaccine within 4 weeks prior to study entry
Killed vaccine within 2 weeks prior to study entry
Absence of spleen
Blood products within 6 months prior to study entry
Previous dengue virus or other flavivirus (e.g., yellow fever virus, St. Louis encephalitis, West Nile virus) infection
Prior receipt of yellow fever or dengue vaccine (licensed or experimental)
Plans to travel to an area where dengue infection is common
Received an investigational agent within 30 days prior to study entry
Other condition that, in the opinion of the investigator, would affect participation in the study
Pregnant or breastfeeding

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00322946

Locations


United States, Tennessee
	Vanderbilt University School of Medicine	Recruiting
	Nashville, Tennessee, United States, 37232-2581
	Contact: Peter Wright, MD 615-343-6260
	Principal Investigator: Peter Wright, MD

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Center for Immunization Research

Investigators


Principal Investigator:	Anna Durbin, MD	Center for Immunization Research (CIR), Johns Hopkins School of Public Health

More Information

Publications:

Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine. 2000 May 26;18 Suppl 2:44-7.

Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol. 2006 Spring;19(1):10-32.

Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, Thumar B, Murphy BR, Karron RA. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis. 2005 Mar 1;191(5):710-8. Epub 2005 Jan 27.

Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg. 2001 Nov;65(5):405-13.

Responsible Party:	Center for Immunization Research, Johns Hopkins School of Public Health ( Anna Durbin, MD )
Study ID Numbers:	CIR 221, WIRB Protocol Number 20061807
First Received:	May 4, 2006
Last Updated:	January 10, 2008
ClinicalTrials.gov Identifier:	NCT00322946
Health Authority:	United States: Food and Drug Administration

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Dengue Fever

Dengue Vaccine

Dengue Virus

Dengue Hemorrhagic Fever

Dengue Shock Syndrome

Study placed in the following topic categories:

Virus Diseases

Fever

Hemorrhagic Fevers, Viral

Shock

Dengue

Hemorrhagic fever

Viral hemorrhagic fever

Dengue fever

Healthy

Arbovirus Infections

Dengue Hemorrhagic Fever

Additional relevant MeSH terms:

RNA Virus Infections

Flaviviridae Infections

Flavivirus Infections

ClinicalTrials.gov processed this record on September 05, 2008

Sponsors and Collaborators:	National Institute of Allergy and Infectious Diseases (NIAID) Center for Immunization Research
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00322946